Announcements Trials
Browse Landscape

Status

Recruiting 1626Active not recruiting 849Completed 350Not yet recruiting 286Terminated 143Withdrawn 26Available 25Enrolling by invitation 23Suspended 14No longer available 4Temporarily not available 1Approved for marketing 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Expanded_access 4

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Granuloma, Plasma Cell 1Glioma 1Carcinoma, Renal Cell 1Adenocarcinoma of Lung 1

Interventions

ceritinib 1capmatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × 90 days × Clear all
NCT06090331 2026-05-29

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Telix Pharmaceuticals (Innovations) Pty Limited

No longer available
Genitourinary

Carcinoma, Renal Cell

NCT06743100 2026-05-29

18F-Floretyrosine Expanded Access Program

Telix Pharmaceuticals (Innovations) Pty Limited

No longer available
CNS

Glioma

NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

Novartis

No longer available
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

Novartis

No longer available
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡